By the end of week 4, people in the main trial had lost 3.2% of their body weight on average, which is about 7 lb for someone starting at 231 lb. The placebo group had lost 1.1%.
The 2.5 mg dose exists to introduce the drug. The FDA label calls it a dose "for treatment initiation" and says it is "not approved as a maintenance dosage".1 So the first month is a warm-up, and its job is to get your body used to the drug before the dose rises to 5 mg in week 5.
This page follows that month in order: the first injection, the first few days, each of the four weeks, and the decision at the end. Where the trials measured something, the number is here. Where they did not, and the first week is one of those gaps, the page says so.
What happens when in the first month?
Enter the day and time of your first injection. The list gives the dates that matter, and the chart shows how the level of drug builds over the first six weeks.
Log the first dose in the app and it keeps these dates for you, with the site you used.
Open the appDates follow the label's schedule. The level is a model from the label's half-life (5 days) and time to peak (24 hours); 100% is the settled weekly peak on 2.5 mg. The numbers along the bottom are days of treatment. It is not a blood test.
The shape of that chart explains most of what people report in the first month. The first dose reaches about 61% of the level the body will settle at on 2.5 mg, and then the level drops through the week to about 28% before the second dose. Each new dose lands on what is left of the last one, so the second peak is higher than the first and the third is higher again. By the fourth week the peaks have stopped growing. The label puts it in one line: "Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration."1
What should I know on the day of the first injection?
The label's instructions for the injection itself are short, and they do not change later.1
The first dose
The liquid should be "clear and colorless to slightly yellow", and a pen with particles or a changed colour is not used. The label expects you to be shown how to inject before the first dose, and to be trained again if your prescription later changes from one device to another, for example from pens to vials.
Nothing in the label ties the first dose to a particular time of day or to an empty stomach. If you want the first peak to fall on a quiet day, count about 24 hours forward from the injection. No trial compared morning with evening doses.
What happens in the first three days?
The drug is absorbed slowly from under the skin. The label gives the time to the highest level in the blood as 24 hours at the median. It can be as short as 8 hours and as long as 72.1 For most people the peak of the first week falls on the second day. For some it is the same evening, for others the fourth day.
The first dose also has the strongest effect on the stomach. Zepbound slows the rate at which the stomach empties, and the label reports that this effect "was greatest after a single dose of 5 mg and diminished after subsequent doses". The study behind that sentence used a painkiller as a tracer: after a first dose of tirzepatide, the peak level of acetaminophen in the blood was 55% lower and came an hour later. By week 6 of treatment the same test showed "no meaningful impact".1
In daily terms, food stays in the stomach longer in the first days than it will at any later point at the same dose. Fullness comes sooner and lasts longer. A meal of your usual size may feel like too much. This is the effect that the advice from the trials, described below, is built around.
Will I lose weight or feel side effects in the first week?
The trials cannot tell you, because they did not look. The first weight the label reports after the start of SURMOUNT-1, the main trial,2 is at week 4.1 No published trial reports weight or side effects for week 1 alone. Any chart that shows a figure for the first week, including a pound count, was not taken from the trials.
What can be said is indirect. The level in week 1 is the lowest it will ever be while you are on the drug: one dose of 2.5 mg, against six times that amount per week on 15 mg, and no carry-over from earlier doses. At the same time the stomach effect is at its strongest. You may notice a change in appetite within days, or nothing at all. The trial results give no sign that either one predicts how the following months will go, as a later section shows.
What changes from week 1 to week 4?
The dose is the same in all four weeks. The amount of drug in the body is not, and neither is the way the stomach reacts to it. The table puts the model next to what the label says.
| Week | Peak level | Lowest level | What the label says |
|---|---|---|---|
| 1 | 61% | 28% | Stomach slowing is at its strongest |
| 2 | 85% | 38% | The stomach effect is already fading |
| 3 | 94% | 42% | Rotate the site with each dose |
| 4 | 98% | 44% | Steady state after 4 weeks; first weight result |
Level as a share of the settled weekly peak on 2.5 mg, from the model described at the end of the page.
Two curves cross during the month. The drug level climbs week by week, while the body's reaction to each dose shrinks. That is why the first month does not get steadily harder even though more drug is on board in week 4 than in week 1. It is also why the label fixes the starting period at 4 weeks and not 2: by week 2 the level is still well short of where it will settle.
A useful routine for these four weeks is short. Weigh yourself once a week, on the same day and at the same time, since daily weights swing by more than the weekly change you are looking for. Note the day of any side effect, counted from the injection. Use a new site for each dose. If you take a birth-control pill, keep the backup method going until day 28.
How much weight do people lose in the first month?
At the end of week 4, after four doses of 2.5 mg, the average loss in the Zepbound groups was 3.2% of starting weight. The placebo group, which got the same diet and activity counselling without the drug, had lost 1.1%.1 Enter your weight to see both in pounds, and move on to weeks 8 and 12 to see where the first step-ups led.
Weigh in once a week in the app and it draws your line next to the trial average.
Open the appAverages of the 10 and 15 mg groups of SURMOUNT-1, read from Figure 3 of the label. Until week 12 these groups took the same doses: 2.5, then 5, then 7.5 mg.
Two things about the week-4 figure are easy to miss. A third of it also happened on placebo. Everyone in the trial was counselled to eat about 500 kcal a day less than they burned and to be active for at least 150 minutes a week, starting with the first dose.1 The first month's result is the drug plus that programme.
And 3.2% is an average with wide spread around it. A later analysis of the same trial found that 18% of people who took most of their doses had lost less than 5% even by week 12. Nine in ten of them reached 5% by week 72, and on average it took them 25 weeks.4 A flat scale in the first month is common and does not mean the drug has failed. Our week-by-week chart follows every dose to week 72.
How likely are side effects in the first month?
The label does not break side effects down by week or give figures for 2.5 mg alone. It gives totals over as long as 72 weeks, for people who went on to 5, 10 or 15 mg. Those totals are an upper limit for the first month, since they include every later dose increase.
Over that whole period, stomach and bowel side effects of any kind were reported by 56% of people on Zepbound and 30% on placebo. Nausea was reported by 25 to 29 in 100, diarrhea by 19 to 23, constipation by 11 to 17 and vomiting by 8 to 13.1 Read the other way round, more than 70 in 100 never reported nausea, and about 9 in 10 never vomited.
The label is specific about timing in one respect: most nausea, vomiting and diarrhea "occurred during dose escalation and decreased over time". The first month is the first stretch of that escalation. A pooled analysis of the four main trials adds detail on severity. Most of these side effects were mild to moderate. Severe or serious ones occurred in 0.3% to 5.6% of people, depending on the trial.3
The same analysis counted how many people ended up taking something for their symptoms. Across three of the trials, 13.8% to 27.5% of people on tirzepatide used an anti-nausea medicine at some point, against 5.8% to 6.7% on placebo. For anti-diarrhea medicine the figures were 5.2% to 9.3% against 1.2% to 2.2%. First use was most common in the first 24 weeks.3
What other effects does the label list?
Stomach and bowel symptoms get most of the attention, but the label's table has more rows. These are the ones people most often ask about, again counted over the whole trial and compared with placebo.1
| Reported by, in 100 people | Zepbound | Placebo |
|---|---|---|
| Stomach pain | 9 to 10 | 5 |
| Indigestion | 9 to 10 | 4 |
| Reaction at the injection site | 6 to 8 | 2 |
| Tiredness | 5 to 7 | 3 |
| Burping | 4 to 5 | 1 |
| Heartburn or reflux | 4 to 5 | 2 |
| Hair loss | 4 to 5 | 1 |
| Dizziness | 4 to 5 | 2 |
Each of these was reported by fewer than 1 person in 10. Tiredness and dizziness matter in the first weeks for a practical reason: eating and drinking much less than usual can cause both by itself, with no help from the drug, so they are a prompt to check your fluids and meals before blaming the injection. The table does not say in which month each effect appeared.
If I feel no side effects, is it working?
Yes. This is one of the most asked questions in patient forums, usually in the form "who did not have nausea?", and the trials answer it directly. Researchers split the participants of SURMOUNT-1 into those who reported nausea, vomiting or diarrhea at any point and those who reported none of the three, and compared their weight at the end.3
Uses the starting weight you entered above. Post hoc analysis: the groups were not assigned at random, so the gap shows an association and is not proof of cause.
People who never had any of the three symptoms lost 15.3%, 20.6% and 22.2% of their weight on 5, 10 and 15 mg. People who had at least one lost 17.2%, 22.2% and 22.8%. The difference is between half a point and two points. The authors estimated that these side effects accounted for at most 3.1% of the total weight reduction and concluded that they "appeared to contribute slightly".3
So the drug does not work by making people feel sick, and a quiet first month says nothing bad about what is coming. A second analysis looked at the question from the other side and found that the pattern, severity and timing of stomach side effects were similar in people who lost weight early and in those who did not.5
How should I eat in the first weeks?
The trials had a standard answer, and it is the only eating advice with trial results attached to it. Participants who had stomach symptoms they could not tolerate were first counselled on three changes: eat smaller meals, split three daily meals into four or more smaller ones, and stop eating when you feel full.3
All three follow from the slow stomach of the first days. A stomach that empties slowly is full for longer, and a meal sized for your old appetite arrives on top of the previous one. Smaller portions more often give it time. "Stop when full" sounds too obvious to be advice, but on this drug fullness arrives earlier in a meal than habit expects, and the last third of a normal plate is where the trouble starts.
The trials also had steps for when food changes were not enough. In order: a medicine for nausea or diarrhea, prescribed by the trial doctor; skipping one weekly dose and resuming at the same dose; dropping to the next lower dose; and, if nothing helped, stopping the drug.3 Outside a trial each of those steps is your prescriber's call. The order is useful to know, because it shows that stopping was the last resort and several things were tried first.
Fluids deserve their own line. The label warns that vomiting and diarrhea can lead to dehydration, and that dehydration has caused kidney problems in people taking this class of drug. Its advice to patients is to drink fluids to reduce that risk.1 A reduced appetite often brings reduced thirst with it, so in the first weeks drinking is something to do on purpose.
What the trial asked of people besides the injection
The results on the label were not produced by the drug alone. From the first dose, participants in the main trials got instruction on a reduced-calorie diet with a deficit of about 500 kcal a day, counselling to be physically active for at least 150 minutes a week, and counselling on behaviour change.1 The placebo group got all of it too, which is how the trial could separate the drug from the programme.
One trial put the programme first. In SURMOUNT-3, 806 people began with 12 weeks of intensive lifestyle changes and no drug. The 579 who lost at least 5% of their weight in that time were then assigned to Zepbound or placebo.1 The design is a reminder that a first month with careful eating and regular activity is doing part of the work, and that the two were always meant to go together. The label itself describes Zepbound as a treatment "in combination with a reduced-calorie diet and increased physical activity".
What do people wish they had known before starting?
The question comes up again and again in patient communities. Six answers have support in the label or the trials.
- The starting dose is not the treatment dose. 2.5 mg is a half to a sixth of the doses the results were measured on. Judging the drug by the first month is judging it by its introduction.
- Birth-control pills need backup for the first 4 weeks. The label advises switching to a non-oral method or adding a barrier method "for 4 weeks after initiation" and again for 4 weeks after each dose increase.1
- Other pills may be absorbed more slowly at first. The label says Zepbound "has the potential to impact the absorption" of medicines taken by mouth, and asks for monitoring of drugs where the exact level matters, with warfarin as its example.
- The first dose is felt in the stomach more than later ones. The slowing of the stomach is strongest after the first exposure and fades.
- Part of the early loss is the programme. A third of the week-4 result appeared on placebo with the same counselling.
- You do not need to feel sick for it to work. People with no nausea, vomiting or diarrhea lost nearly as much as people with them.
Which medicines need attention in the first month?
Three groups, all named in the label.1
Insulin and sulfonylureas. Zepbound lowers blood sugar, and together with these diabetes medicines it can lower it too far. The label says the dose of insulin or the sulfonylurea may need to be reduced. If you take either, the plan for that belongs in the conversation before the first injection.
Oral contraceptives. As above: 4 weeks of backup from the first dose. Contraceptives that are not swallowed "should not be affected".
Medicines with a narrow margin. For drugs that depend on a threshold level, the label asks for monitoring when they are taken with Zepbound. Ask whoever prescribes them whether a check is due in the first weeks.
Which symptoms in the first weeks are not normal?
Nausea that comes and goes, a smaller appetite, looser or slower bowels and burping are the expected kind. The patient section of the label lists symptoms that are different and asks for action on each.1
| Symptom | What the label says to do |
|---|---|
| Severe stomach pain that will not go away, with or without vomiting, sometimes felt through to the back | Stop using Zepbound and call your healthcare provider right away |
| Swelling of the face, lips, tongue or throat; trouble breathing or swallowing; severe rash; fainting; very rapid heartbeat | Stop using Zepbound and get medical help right away |
| Pain in the upper stomach with fever, yellowing of the skin or eyes, or clay-coloured stools | Tell your healthcare provider |
| Vomiting or diarrhea that does not stop, or not being able to drink | Call your healthcare provider; drink fluids to avoid dehydration |
| A lump or swelling in the neck, hoarseness, trouble swallowing, shortness of breath | Tell your healthcare provider |
The first row describes possible inflammation of the pancreas, the second a serious allergic reaction, the third gallbladder problems. They are uncommon. They are listed here because the first month is when a new symptom is most likely to be put down to "getting used to it".
I feel nothing on 2.5 mg. Should the dose go up sooner?
The label does not allow it. The starting dose is taken "for 4 weeks", and the first increase comes after those 4 weeks.1 The chart at the top of the page shows why the wait is built in: the level from 2.5 mg is still rising until the fourth dose. Asking for 5 mg in week 2 means asking for a second drug level before the first one has arrived.
There is evidence on what happens when the climb is faster. In a 12-week study of three schedules, the groups that reached high doses in bigger jumps reported nausea at rates of 35.7% and 39.3%, against 24.1% in the group with a slower, even climb. The authors concluded that "lower starting doses and smaller dose increments are associated with a more favourable side effect profile".6
Feeling nothing in the first month is also not a forecast. The slow starters described above, people under 5% at week 12, mostly got there later. What the first month can tell you is how you tolerate the drug, and that is the information the label asks your prescriber to use.
How do I know the first month went well?
By the two things the label tells the prescriber to weigh before any change of dose: "treatment response and tolerability".1 Neither needs a lab test. Both are easier to judge from notes than from memory.
- Response. Your weight at the start and at the end of week 4. The trial average was a 3.2% loss, with a wide spread. Any loss counts, and no loss yet is common.
- Tolerability. Which side effects you had, on which day after the injection, and whether they were weaker in week 4 than in week 1. Fading is the expected pattern.
- Anything on the warning list. If one of those symptoms appeared, the prescriber should hear about it before the next dose, not at the next appointment.
A month with some weight loss and side effects that faded is the textbook case for moving to 5 mg on schedule. A month with stubborn side effects is a reason to talk before the step. In the trials the usual sequence was food changes first, then a medicine for the symptom, and only after that a change to the dose.
What happens at the end of the first month?
On day 29 the label's schedule moves to 5 mg, the first of the three maintenance doses. After that the dose "may be increased in 2.5 mg increments, after at least 4 weeks on the current dose", up to 15 mg.1 The step from 2.5 to 5 mg is the only one in the schedule that doubles the dose, and the level in the body doubles with it over the following four weeks. If the first month was easy, that is a good sign for this step, but the second month is the one in which the dose first reaches a level that was tested long term.
Our dosing schedule page puts dates on every step after this one and shows what each maintenance dose delivered. If a dose in the first month is late, the rule is on the missed dose page: it can be taken up to 4 days after it was due.
What should I know about the pens in the first month?
A first prescription covers the four starting doses, and the storage rules are the part people most often learn late.1
Storing single-dose pens and vials
Rotating the injection site starts with the second dose: the label says to "rotate injection sites with each dose". The abdomen, thigh and upper arm deliver the same amount of drug, according to the label's pharmacology section, so the choice among them is about comfort.
Short answers to common questions
How soon does Zepbound start working?
The drug is in the blood within hours and peaks about a day after the first injection. The first measured weight result in the trial is at week 4: an average loss of 3.2%, against 1.1% on placebo.
Is 7 lb in the first month typical?
It is the trial average for someone starting at 231 lb. For 180 lb the same 3.2% is about 6 lb, and for 300 lb about 10 lb.
Can I inject at night?
Yes. The label allows any time of day, with or without a meal.
I had no nausea at all. Is my dose too low?
No. More than 70 in 100 people never reported nausea in the trials, and those without stomach side effects lost nearly as much weight.
Do side effects come back with every dose increase?
The label says most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time. Each step is a smaller relative jump than the one before it.
What if I vomit after the injection?
The dose is under the skin and is not lost. If vomiting continues or you cannot drink, the label says to contact your healthcare provider.
How the numbers on this page were produced
Dates in the first tool follow section 2.1 of the label: one 2.5 mg dose a week for 4 weeks, then 5 mg. The level curve is a one-compartment model with first-order absorption that uses the label's half-life of about 5 days and median time to peak of 24 hours. It gives 61%, 85%, 94% and 98% of the settled peak after doses one to four, which agrees with the label's statement that steady state is reached after 4 weeks. It is a picture of timing and it cannot show your own blood level.
Weight at weeks 4, 8 and 12 was read from Figure 3 of the label, the same way as on our chart page: marker by marker, calibrated against the numbers printed on the figure. The comparison by side effects comes from a post hoc analysis of SURMOUNT-1 published in 2025, and it describes groups that formed on their own. It shows that weight loss did not depend on feeling sick. It cannot show what would have happened to a given person.
Sources
- ZEPBOUND (tirzepatide) prescribing information and Medication Guide, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2, 5, 6, 7, 12, 14 and 16, Table 1, Figure 3. accessdata.fda.gov
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. doi:10.1056/NEJMoa2206038
- Rubino DM, Pedersen SD, Connery L, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab 2025;27:1826-1835. doi:10.1111/dom.16176
- Ard J, Lee CJ, Gudzune K, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes Obes Metab 2025;27:5064-5071. doi:10.1111/dom.16554
- Kokkinos A, Thethi T, Lee CJ, et al. Tirzepatide efficacy and tolerability according to early weight response: a post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials. Diabetes Obes Metab 2026;28:8367-8377. doi:10.1111/dom.71009
- Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab 2020;22:938-946. doi:10.1111/dom.13979
Related analyses
Zepbound side effects timeline: when they start, how long they last, when they ease
Mounjaro side effects: how common each one is by dose, and when they ease
Ozempic side effects: how common each one is by dose, and when they ease
Wegovy side effects: how common each one is, when it peaks and how long it lasts
Log your first dose and watch the first month day by day.
Open Dose Insider